<DOC>
	<DOCNO>NCT01564056</DOCNO>
	<brief_summary>The purpose study evaluate benefit adjuvant chemotherapy overall survival elderly patient breast cancer , sub group high risk relapse accord Genomic Grade test .</brief_summary>
	<brief_title>Adjuvant Systemic Treatment ( ER ) -Positive HER2-negative Breast Carcinoma Women Over 70 According Genomic Grade ( GG ) : Chemotherapy + Endocrine Treatment Versus Endocrine Treatment</brief_title>
	<detailed_description>The purpose trial address question add value adjuvant chemotherapy survival 70+ BC patient ER+ disease , deem `` risk relapse '' ( pN+ pN0 high prognostic classifier , namely GG RT-PCR ) plan receive well adjuvant endocrine treatment . This benefit weigh competition exert comorbidities mortality . As many recently develop trial evaluate specific strategy elderly ( e.g . CALGB 49907 ( 8 ) ; bevacizumab colorectal cancer PRODIGE 20 elderly program support PHRC 2010 ) , choice chemotherapy regimen leave investigator 3 `` standard '' one : TC x 4 ( anthracyclines ) , AC x 4 MC x 4 ( good cardiac tolerance ) , order obtain enrolment less highly select population , representative general population difference high selection classically observed standard oncology trial . In parallel , patient include randomized part ( whatever reason ) treat adjuvant endocrine treatment follow separate observational cohort . 1 . Screening All woman 70+ undergone surgery invasive pN0 pN+ , ER+ HER2- BC , screen invited participate . Pre-selection possible pre-operatively . 2 . Prognostic signature After sign write informed consent , prognostic signature Genomic Grade ( GG ) assess RT-PCR . 3 . Randomization ( Group I ) Only patient Genomic Grade ( GG ) consider high randomize ( 1:1 ) : endocrine treatment ( Arm A ) versus endocrine treatment + adjuvant chemotherapy ( Arm B ) . Randomization1:1 arm A B do use minimization stratify accord pN status ( pN+ v pN0 ) , G8 ( ≤ v &gt; 14 ) , center . Given ( ) high potential less cardiotoxic regimen include liposomal formulation anthracyclines exclude anthracyclines ( ii ) wish capture whole population depict heterogeneity age 70 , adjuvant chemotherapy ( Arm B ) leave choice investigator amongst 3 standard regimen duration , 4 cycle give every 3 week + primary prophylactic GCSF : - AC = doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m² - TC = docetaxel 75 mg/m² + cyclophosphamide 600 mg/m² - MC = liposomal non pegylated doxorubicin ( Myocet ) 60 mg/m² + cyclophosphamide 600 mg/m² 4 . Patients randomized ( Group II ) Patients randomized reason ( low GG , randomization refusal treatment refusal , etc . ) enter surveillance program able participate specific geriatric study ( GERICO project evaluate impact comprehensive geriatric assessment quality life , treatment administer BC survival 75 year ; EORTC study validate scale specifically develop elderly ELD15 ) . The Group II present triple interest participate , together randomized patient , achieve follow objective : - validation prognostic value Genomic Grade performance test elderly BC population , compare standardized routine histopathological parameter , - translational study identify molecular signature , - collection descriptive data include comorbidities polymedication . 5 . Endocrine treatment radiotherapy In Groups ( I II ) , endocrine treatment leave choice investigator ( tamoxifen , aromatase inhibitor sequential ) radiotherapy follow standard guideline .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women age ≥ 70 yo , Histologically proven invasive breast cancer ( regardless type ) , Complete surgery perform enrolment : radical modify mastectomy breast conservative surgery , either sentinel lymph node procedure axillary lymph node dissection , Any N status ( pN+ pN0 ) , No clinically radiologically detectable metastasis ( M0 ) , Oestrogen receptor ( ER ) positive , define ≥ 10 % tumor stain cell immunohistochemistry ( IHC ) , HER2 negative status ( i.e . IHC score 0 1+ , IHC score 2+ FISH/SISH/CISH negative ) , Normal haematological function : ANC ≥ 1,500/mm3 ; platelet count ≥ 100,000/mm3 ; haemoglobin &gt; 9 g/dl , Normal hepatic function : total bilirubin ≤ 1.25 ULN ; ASAT ALAT ≤ 1.5 ULN ; alkaline phosphatase ≤ 3 ULN , Creatinine clearance ( MDRD formula ) ≥ 40 mL/min , PS ( ECOG ) ≤ 2 , Patient able comply protocol , Patients must sign write informed consent form prior study specific procedure , include agreement use archive tumoral material genomic screening data collection , Patients must affiliate Social Health Insurance . Any metastatic impairment , include homolateral subclavicular node involvement , regardless type , Any tumor ≥ T4a ( UICC1987 ) ( cutaneous invasion , deep adherence , inflammatory breast cancer ) , ERnegative breast cancer ( i.e . &lt; 10 % tumor stain cell IHC ) , HER2 overexpression , define IHC score 3+ score 2+ FISH/SISH/CISH positive , Any chemotherapy , hormonal therapy radiotherapy breast cancer surgery , PS ( ECOG ) ≥ 3 , Any specific contraindication study drug ( include limit hypersensitivity study drug component ) , Patient deprive freedom tutelage , Patient unable comply require medical followup geographic , social psychological reason .</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Adjuvant systemic treatment</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Elderly patient</keyword>
</DOC>